i-net - Promotion of Innovation in Northwestern Switzerland
i-net - Promotion of Innovation in Northwestern Switzerland
Discipline: Innovation
The mission of i-net innovation networks switzerland is to promote innovation in Northwestern Switzerland. As a public private partnership between the cantons of Aargau, Baselland, Basel-Stadt, Jura and leading companies from the region, i-net supports companies in the technology fields of ICT, Life Sciences, Medtech, Cleantech and Nanotechnology. i-net offers companies and innovating entrepreneurs free advisory services and a wide range of opportunities to network and foster knowledge and technology transfer. With around 50 events per year i-net addresses a network of over 5500 people - from start-ups to global companies.
Roche presented development plans for its Basel site. Over the next 10 years, Roche will invest 3 billion Swiss francs in the development of its Basel site. Under the site development plan, developed in collaboration with architects Herzog & de Meuron, a large part of the Basel workforce will be brought together on the main site around Grenzacherstrasse.
Solid-state lighting (SSL) represents a revolution in the lighting domain, comparable to the invention of the incandescent bulb in the 19th century. SSL devices such as semi-conductor-based light-emitting diodes (LEDs) or organic light-emitting diodes (OLEDs) are the light sources of the future.
Archroma, a Reinach-based company focussing on specialty chemicals for the textile, paper and emulsions sectors and a portfolio company of US-based private investment firm SK Capital Partners, announced that they have entered an agreement to acquire the global textile chemicals business of BASF.
Wie Bisnode D&B mitteilt, wurde von Januar bis September 2014 über 3'091 Unternehmungen in der Schweiz ein Insolvenzverfahren eröffnet. Laut Mitteilung ist dies eine «deutliche Abnahme um acht Prozent gegenüber der Vorjahresperiode».
Genentech, the US subsidiary of Roche, announced final survival results from the Phase III «Cleopatra» study, which showed that adding Perjeta to Herceptin and docetaxel chemotherapy extended the lives of people with previously untreated HER2-positive metastatic breast cancer by 15.7 months.
NewLink Genetics, an US based biotech, which focuses on discovering, developing, and commercializing novel immunotherapeutics, announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group for the development of NLG919, NewLink's IDO pathway inhibitor.
Unter dem Titel «Werkstatt Basel» veranstaltet die Handelskammer beider Basel (HKBB) - eine Partnerorganisation von i-net - noch bis Januar 2015 insgesamt sechs Werkstätten mit Referaten, Diskussionsrunden und Publikums-Voting.
Seit mehr als 20 Jahren führt die Junge Basler Wirtschaftskammer (JCI Basel) zweitägige Betriebsgründungsseminare im Biozentrum der Universität Basel durch. Laut Mitteilung referieren an den zwei Seminartagen jeweils erfahrene Referenten zu Themen, mit denen sich Betriebsgründer auseinandersetzen müssen (z.B. Versicherungen, Finanzierungen, Rechtliches, etc.).
Die Organisation für wirtschaftliche Zusammenarbeit und Entwicklung (OECD) hat anhand von neun Faktoren die Lebensqualität in verschiedenen Regionen gemessen und die Ergebnisse publiziert. 362 Regionen aus insgesamt 34 OECD-Mitgliedstaaten wurden miteinander verglichen, die Schweiz wurde in die sieben Grossregionen aufgeteilt.
Most experts believe that combining immunotherapies with existing treatment options such as chemotherapies, radiation, targeted cancer therapies (and importantly also with cancer vaccines, many of which are currently under development) holds great potential and several collaborations have recently been announced pursuing this strategy.
